key: cord-1023287-1b09piwd authors: Goel, Nikky; Ahmad, Razi; Fatima, Huma; Khare, Sunil Kumar title: New threatening of SARS-CoV-2 co-infection and strategies to fight the current pandemic date: 2021-03-17 journal: Med Drug Discov DOI: 10.1016/j.medidd.2021.100089 sha: 4d74a32ca3a8337b8bbce174420e8de01609a234 doc_id: 1023287 cord_uid: 1b09piwd Coronavirus disease (Covid-19) is a global pandemic. The Covid-19 outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overloaded healthcare systems that need medication to be rapidly established, at least to minimize the incidence of Covid-19. The co-infection with other microorganisms has drastically affected human health. Due to the utmost necessity to treat the patient infected with Covid-19 earliest, poor diagnosis and misuse of antibiotics may lead the world where no more drugs are available even to treat mild infections. Besides, sanitizers and disinfectants used to help minimize widespread coronavirus infection risk also contribute to an increased risk of antimicrobial resistance. To ease the situation, zinc supplements' potentiality has been explored and found to be an effective element to boost the immune system. Zinc also prevents the entry of the virus by increasing the ciliary beat frequency. Furthermore, the limitations of current antiviral agents such as a narrow range and low bioavailability can be resolved using nanomaterials, which are considered an important therapeutic alternative for the next generation. Thus, the development of new antiviral nanoagents will significantly help tackle many potential challenges and knowledge gaps. This review paper provides profound insight into how Covid-19 and antimicrobial resistance (AMR) are interrelated and the possible implications and current strategies to fight the ongoing pandemic. Covid-19 being a viral infection, antibiotics are commonly used at a rising pace to support and prevent infections. This review paper focuses on providing deep insight into how Covid- 19 and AMR are an interlinked and present focus areas working to combat the ongoing pandemic. Co-infections with other microorganisms such as bacteria, fungi, and other viruses are commonly associated with respiratory viral infections. Co-infections are directly associated with a rise in morbidity and mortality rates, requiring early diagnosis and specific treatment. For example, most deaths were due to co-infections during the influenza epidemic in 1918, with other bacteria mainly due to Streptococcus pneumonia [12] . Still, the occurrence of SARS-CoV-2 bacterial co-infections is not well defined, and there is a knowledge gap in the understanding and lack of evidence to support the bacteria-virus association [13] . Given the [14, 15] . Bengoechea and Bamford envision three non-mutually exclusive bacterial/SARS-CoV-2 co-infections scenarios: secondary SARS-CoV-2 following bacterial infection/colonization; combined viral/bacterial pneumonia; secondary bacterial "superinfection" after SARS-CoV-2 depicted in Fig 2 [15] . Highly qualitative and time-dependent, underlying mechanisms of these scenarios involve dynamic interactions among three (virus, host, and bacteria) different entities. However, it is evident that in a combination of viral/bacterial pneumonia, the SARS-CoV-2 immune response is probably altered. They completely postulate that any co-infection situation would eventually exacerbate the clinical outcome severity of Covid-19. SARS-CoV-2 may strengthen bacterial colonization and mediated bacterial infection improvement is not uncommon. The airway epithelium invasion by respiratory pathogens is increased by rhinovirus and influenza virus infections [16] . The exponentially rising concern of SARS-CoV-2 has put everything else in the shade, including the ever-growing AMR, the global issue. Even after this pandemic, problems will persist, which may be exacerbated if proper measures are not taken to treat and recommend antibiotics. A current study on Covid-19 has reported 3.5%of bacterial coinfections and nearly 14% of secondary infections. The bacterial co-infection rate varies with the patient's populations and the criticality of the diseases. The majority of the affected people with Covid-19 have preliminary symptoms of high fever, cough, and shortness of breath. Despite Covid-19 being a viral infection, the doctor has to prescribe the antibiotics since high fever, radiological infiltrates, cough are hallmarks of bacterial acquired pneumonia, which required immediate antibiotic treatment. Even patients with mild symptoms of Covid-19 had been prescribed azithromycin along with hydroxychloroquine despite the lack of evidence supporting the efficacy of these drugs [12] . The urgency of treatment, absence of antiviral drugs with proven efficacy, and uncertainty about Covid-19 infection has worsened the situation. The effect of Covid-19 on AMR is one dimension that required requisite attention. The SARS-CoV-2 outbreak is internationally superimposed on the ongoing multidrugresistant bacteria pandemic. According to the National Institute for Health and Care Excellence (NICE) guidelines for treating severe pneumonia, patients will be given broadspectrum antibiotics (amoxicillin or doxycycline) as an alternative in the United Kingdom regardless of cause. About 15 to 50 percent of bacterial isolates from a blood sample are resistant to as a minimum one antimicrobial group and collective resistance to various antimicrobial groups in most European countries, building it probable that broad pragmatic hospitals, contributing to a rise in death due to the insufficient armory of antibiotics for hospital-acquired infections treatment. After surgery, transplantation, or chemotherapy, the treatment of patients may be significantly affected. The transmission of AMR to the community should not be ignored and the direct effect on the healthcare environment. The more considerable amount of released antimicrobials from hospital wastewater leads to increased antimicrobial in the ecosystem, impacting resistance levels in animals (animal feed and wildlife) and agricultural and natural systems [15, 21, 22] . All in all, particularly in these difficult times, antibiotic stewardship standards should not be relaxed. It is important to immediately determine a need for antibiotic treatment and avoid it if not needed. Ideally, if antibiotics are essential, the microbiology lab should suggest which ones are most suitable based on the microorganism and the resistance pattern [23] . The improved utilization of hand sanitizers and antibacterial soaps as protection against SARS-CoV-2 is one final factor to consider. Although do not argue against this practice, it emphasizes that they may contain extra chemicals that do not affix safety but may boost antimicrobial bacterial resistance instead. To develop resistance against disinfectants, bacteria manipulate efflux pumps, and these same efflux pumps lead to AMR [24] . In any event, to prevent the selection of bacteria with increased tolerance/resistance to antimicrobials, the public must adhere to the manufacturer's instructions for proper use. Zhu et al. showed that among 257 Covid-19 patients used in the study, 243 (94.2%) were co-infected [25] . Bacterial co-infection was dominant when tested for 39 test microorganisms, including bacteria, viruses, and fungi, using pathogen-specific real-time PCR techniques. S. pneumoniae, followed by Klebsiella pneumoniae and Haemophilus influenzae, were the most widespread. However, they are conditional pathogenic but are pathogenic if the immune response of Covid-19 infected patients is not successful or decreased. Patients were divided into four groups, of which 8.5% were asymptomatic cases, 30 .4% were mild cases, 54.5% were moderate cases, and 6.6% were severe cases. Among the extreme groups, the highest rates of co-infection were found with bacteria and fungi. Therefore, simultaneous screening for other respiratory pathogens is required while testing SARS-CoV-2for proper treatment and diagnosis. When one or several bacteria infect and harm the upper respiratory tract, the other bacteria become prone to quickly infect the area, complicating the diagnosis and treatment efficiency. As a result, certain precautions should be taken to treat co-infection with common bacterial pathogens, especially B. pertussis [26] .It is essential to explain and further validate why B. pertussis increased in Covid-19 positive patients in the next study. others [37, 38] . With the start of the Covid-19 outbreak, hand sanitizers have been significantly elevated, which has positive effects on people's hygienic conditions. On the other hand, this practice may select resistant bacteria, ultimately contributing to elevated AMR threat even more [9] . Moreover, the microbial flora of the human body also has a significant role in human health. Overuse of ABHS may result in an imbalance between the useful and pathogenic bacteria in the digestive system, causing inflammatory bowel diseases, obesity, autism, etc. [39] . Apart from the development of resistant bacteria, the use of ABHS is associated with many other severe issues like poisoning via ingestion, fire hazard, and organ toxicity via skin absorption [37] . Apart from this, repeated use of hand sanitizers and disinfectants may result in various health issues such as changes in skin texture, dryness (cutaneous xerosis), irritant contact dermatitis (ICD), and allergic contact dermatitis (ACD) [40] . These side effects are due to the chemical composition of sanitizers and disinfectants that need to be overcome by the other strategy like boosting the immune system by giving some supplement, developing nanomedicine and the vaccine. Zinc is an essential trace element for the development and function of the immune cells. Zinc is involved in various biological processes as a cofactor, signaling molecule, structure, and regulatory component of the metabolism of carbohydrates and lipids. It also helps in the proper functioning of the cardiovascular, nervous, and reproductive systems [41] . Zinc deficiency results in altered and dysfunction of humoral and cell-mediated immune responses, mostly T-cell mediated, resulting in increased susceptibility to inflammatory and infectious diseases [42, 43] . Under zinc inadequacy condition, organisms are more prone to toxin producing bacteria and enteroviral pathogens, that trigger guanylate and adenylate cyclases, animating chloride discharge, causing diarrhoea and reducing retention of supplements, consequently worsening a previously undermined mineral status [41, 44] . The fact that zincs insufficiency is liable for 16% of all profound respiratory infections worldwide offers a first clear indication that zinc deficiency is associated with the risk of disease and the extreme progression of Covid-19 indicating possible zinc benefits supplementation [45] . Also, Zinc has been shown to have a significant effect on viral infections by modulating the viral particle entry, fusion with the target cell membrane, replication, viral protein translation and processing, further release of viruses, and destabilizing the viral envelope, including those involved in respiratory system pathology [41] . Zn 2+ cations have been shown to inhibit SARS-coronavirus RNA polymerase (RNA dependent RNA polymerase, RdRp) activity, especially in combination with Zn ionophore pyrithione, by reducing its replication [45] . Low-dose zinc supplementation with small amounts of zinc ionophores pyrithione or J o u r n a l P r e -p r o o f Journal Pre-proof hinokitol reduced RNA synthesis by inhibiting RdRp in equine arteritis virus (EAV), poliovirus, picornavirus, influenza, and SARS-CoV [3] . Recent studies have demonstrated the efficacy of chloroquine antiviral activity in treating Covid-19 enhanced by zinc supplementation. However, further investigation of the intimate mechanisms of its antiviral activity is needed. These significant findings indicate that in the treatment of Covid-19, Zn 2+ may be considered as the specific antiviral agent [41] . Nanotechnology is a multidisciplinary area of engineering, chemistry, physics, and medicine. The application of nanotechnology in the field of medicine is referred to as nanomedicines [46] . Nanomedicines are defined as nanoscale tools or with the ability of early detection and prevention of diseases, direct the bioactive molecule to its target of action and monitor its release to ensure optimum concentration over the desired time frame. Nanomedicine is often reported as nanodrugs, nanoconstructs, nanoparticles, nanocarriers, nanomaterials, or nanotherapeutics [47] [48] [49] [50] [51] [52] . Nanoparticles (NPs) have been widely used over the decades due to their nanoscale size, versatility, multifunctionality, adaptability, enhanced solubility, personalized medicines, early diagnosis, and disease prevention [53] [54] [55] [56] . Nanomedicine has been successfully used to improve care in a wide variety of diseases such as neurological, cancer, cardiovascular, and infectious diseases, including HBV, HIV-1, respiratory syncytial virus, and influenza virus [57] [58] [59] . Nanotechnology may hold tremendous promise in the detection, treatment, and prevention of Covid-19 [60, 61] . Moreover, several patents related to CoV have been registered in the field of nanotechnology [57] . The ongoing pandemic impact on the world is terrifying, and vaccination is the most promising solution to prevent the spread and fight the novel CoV outbreaks. To design the vaccine, it is essential first to define the antigen, adjuvant, manufacturing, and delivery device. The antigen is a foreign material specific to the pathogen administered to initiate the host and adjuvant's immune response as a stimulatory agent to boost the host immune response [6] . Nanoparticles enable multiple antigen presentation, stabilizing antigens from degradation by host cell system upon administration, and acting as carriers for target-based delivery. Two fundamental issues adopted technology for vaccine design must address the efficient delivery of antigen to the dendritic cells following the activation of dendritic cells to trigger adaptive immunity [62] . The ability of nanoparticles to deliver multiple antigens helps promote antigen-presenting cells to function more effectively, thereby increasing the immunogenicity and potency of administered vaccines via recognition by T cell receptors [63] . Identifying the target is the first step to design the vaccine to halt infectious microorganisms' pathogenesis. The significant targets identified for CoV vaccine Research suggests that S protein subunits, RBD of the S1 subunit, and S2 subunit derivatives are the prime target epitomes for the SARS/MERS vaccine development. However, knowledge of SARS-CoV-2 specific antigen(s) for under trial vaccine candidates is limited [6, 64, 65] . Gold NPs (AuNPs) are commonly employed in nanovaccines due to their ability to serve as adjuvants in immunization in addition to being an antigen carrier. However, an extensive study on the use of nanoparticles for promising CoVs vaccine development is needed [57] . The development of a vaccine focuses on antigen identification and delivery to achieve a robust immune response. Previous experiences with SARS-CoV and MERS-CoV have allowed the fast growth of immunizing agent candidates [66] . As of 16 Dec 2020, the clinical evaluation includes 56 Covid-19 candidate vaccines, of which 13 are in phase III trials as listed in Table 2 . There are another 166 candidate vaccines in preclinical evaluation. Phase III trials usually require 30,000 or more participants. All high candidate vaccines are going to be administered through intramuscular injection [67] . Covishield, mRNA-1273, Comirnaty BNT162b2, and sputnik V have been submitted to regulatory bodies to get authorized for emergency use. Among these four, two vaccines: mRNA-1273 and Comirnaty BNT162b2, have reported more than 90% protection efficacy based on their ongoing phase III clinical trials study as listed in Table 3 . They have also been granted emergency authorization for their Covid-19 vaccines by the Food and Drug Administration (FDA) [66] . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Middle East respiratory syndrome: emergence of a pathogenic human coronavirus Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity A pneumonia outbreak associated with a new coronavirus of probable bat origin COVID-19 vaccine development and a potential nanomaterial path forward Coronaviruses as the cause of respiratory infections Rapid review protocol: zinc for the prevention or treatment of COVID-19 and other coronavirus-related respiratory tract infections COVID-19 pandemic and antimicrobial resistance: Another call to strengthen laboratory diagnostic capacity in Africa Increasing tolerance of hospital Enterococcus faecium to handwash alcohols Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing Secondary bacterial infections associated with influenza pandemics SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19? Viral and bacterial interactions in the upper respiratory tract Widespread antimicrobial resistance among bacterial infections in a Rwandan referral hospital Antimicrobial resistance in hospitalacquired gram-negative bacterial infections Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use The antibiotic resistance crisis: part 1: causes and threats General principles of antimicrobial therapy Efflux Pump-Driven Antibiotic and Biocide Cross-Resistance in Pseudomonas aeruginosa Isolated from Different Ecological Niches: A Case Study in the Development of Multidrug Resistance in Environmental Hotspots Co-infection with respiratory pathogens among COVID-2019 cases Respiratory bacterial pathogen spectrum among COVID-19 infected and non-COVID-19 virus infected pneumonia patients Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China Diabetes is a risk factor for the progression and prognosis of COVID-19 Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19 Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition The metabolic and immunological characteristics of pregnant women with COVID-19 and their neonates The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality The pathogenesis and treatment of theCytokine Storm'in COVID-19 Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review COVID-19: Critical discussion on the applications and implications of chemicals in sanitizers and disinfectants The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2 Hand sanitizers: is over usage harmful? Frequent hand washing for COVID-19 prevention can cause hand dermatitis: management tips Zinc and respiratory tract infections: Perspectives for COVID-19 The effects of coronavirus on human nasal ciliated respiratory epithelium Zinc increases ciliary beat frequency in a calcium-dependent manner The potential impact of zinc supplementation on COVID-19 pathogenesis Multivalent nanomedicines to treat COVID-19: A slow train coming Antibacterial effect of green synthesized TiO 2 nanoparticles Alpha amylase assisted synthesis of TiO 2 nanoparticles: structural characterization and application as antibacterial agents Phytochemical delivery through nanocarriers: a review Asparaginase conjugated magnetic nanoparticles used for reducing acrylamide formation in food model system Personalized nanomedicine: a revolution at the nanoscale Synthesis of cost-effective magnetic nano-biocomposites mimicking peroxidase activity for remediation of dyes Enzyme immobilization: an overview on nanoparticles as immobilization matrix Cholesterol-oxidase-magnetic nanobioconjugates for the production of 4-cholesten-3-one and 4-cholesten-3, 7-dione Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 Simultaneous immobilization and refolding of heat treated enzymes on TiO 2 nanoparticles Refolding of thermally denatured cholesterol oxidases by magnetic nanoparticles How can nanotechnology help to combat COVID-19? Opportunities and urgent need COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic Exploiting lymphatic transport and complement activation in nanoparticle vaccines Vaccines based on virus-like nanoparticles for use against Middle East Respiratory Syndrome (MERS) coronavirus Nanotechnology for COVID-19: therapeutics and vaccine research Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions Next-generation vaccine platforms for COVID-19